MERCK & CO., INC.
Rahway, NJ, USA
Effective January 11, 2023, Imago BioSciences is now a subsidiary of Merck & Co., Inc., Rahway, NJ USA (known as MSD outside the United States and Canada)
Science-driven.
Patient-focused.
At Imago BioSciences, the science leads us to achieving the greatest patient benefit. While drug development rarely takes a straight path – it’s often marked by twists and turns – following the science is the only way to successfully find new treatments for malignant, life-threatening diseases of the bone marrow.
Imago (i-mắ-go)
(noun) 1. The final and fully developed stage of an insect after its metamorphosis.
In this process of growth and development, the imago stage refers to the fully formed adult – one that has completed its transformation. In our view, the full maturation of a scientific idea or observation in medical research is when new treatments clinically prove their worth to patients. Anything less misses the mark.
About Us
With a new approach to treating malignant, life-threatening diseases of the bone marrow, our team follows the data to find the right applications of our drugs for patients.
Pipeline
Patients with essential thrombocythemia and myelofibrosis need new, safe and effective options. Our pipeline of therapies reflects our aim to address this immense need.
Patients
We see promise for patients through the lens of science. We’re evaluating our lead therapeutic candidate – bomedemstat – in clinical trials with the hope of providing a new potential treatment option.
News
The latest from Imago BioSciences
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc . (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases,...
Read moreImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks)...
Read moreImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - No patients in this Phase 2 study of bomedemstat in advanced myelofibrosis have progressed to acute...
Read more